CD49d treg cells with high suppressive capacity are remarkably less efficient on activated CD45RA - than on naive CD45RA + teff cells

Cellular Physiology and Biochemistry

Volumn 34, Issue 2, 2014, Pages 346-355

  Kraczyk, Britta ^a   Remus, Ralph ^a   Hardt, Cornelia ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

CD45RA; CD49d; Suppression; Teff cell resistance; Treg cell capacity

Indexed keywords

ALPHA4 INTEGRIN; CD45RA ANTIGEN; INTERLEUKIN 7 RECEPTOR; CD45 ANTIGEN;

ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CELL POPULATION; CONTROLLED STUDY; EFFECTOR CELL; FUNCTIONAL STATUS; HUMAN; HUMAN CELL; HYPOTHESIS; IMMUNOREGULATION; IN VITRO STUDY; LYMPHOCYTE; NORMAL HUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; STAINING; T LYMPHOCYTE SUBPOPULATION; CELL HETEROGENEITY; CELL ISOLATION; FLUORESCENCE ACTIVATED CELL SORTING; IMMUNE DEFICIENCY; T EFFECTOR CELL; CELL CULTURE; IMMUNOLOGY;

ERAGROSTIS TEF;

ANTIGENS, CD45; CELLS, CULTURED; HEALTHY VOLUNTEERS; HUMANS; INTEGRIN ALPHA4; T-LYMPHOCYTES, REGULATORY;

EID: 84904533544     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000363004     Document Type: Article

References (31)

1. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155:1151-1164.
2. Hori S, Nomura T, Sakaguchi S: Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299:1057-1061.
3. Fontenot JD, Gavin MA, Rudensky AY: Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003;4:330-336.
4. Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA, Wilkinson JE, Galas D, Ziegler SF, Ramsdell F: Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001;27:68-73.
5. Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, Kelly TE, Saulsbury FT, Chance PF, Ochs HD: The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001;27:20-21.
6. Baecher-Allan C, Viglietta V, Hafler DA. Human CD4+CD25+ regulatory T cells. Semin Immunol 2004;6:89-98.
7. Yagi H, Nomura T, Nakamura K, Yamazaki S, Kitawaki T, Hori S, Maeda M, Onodera M, Uchiyama T, Fujii S, Sakaguchi S: Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells. Int Immunol 2004;16:1643-1656.
8. Baecher-Allan C, Wolf E, Hafler DA: Functional analysis of highly defined, FACS-isolated populations of human regulatory CD4+ CD25+ T cells. Clin Immunol 2005;115:10-18.
9. Dwyer KM, Deaglio S, Gao W, Friedman D, Strom TB, Robson SC: CD39 and control of cellular immune responses. Purinergic Signal 2007;3:171-180.
10. Mandapathil M, Lang S, Gorelik E, Whiteside TL: Isolation of functional human regulatory T cells (Treg) from the peripheral blood based on the CD39 expression. J Immunol Methods 2009;346:55-63.
11. Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, Solomon M, Selby W, Alexander SI, Nanan R, Kelleher A, Fazekas de St Groth B: Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006;203:1693-1700.
12. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Fazekas de St Groth B, Clayberger C, Soper DM, Ziegler SF, Bluestone JA: CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006;203:1701-1711.
13. Yu N, Li X, Song W, Li D, Yu D, Zeng X, Li M, Leng X, Li X: CD4(+)CD25(+)CD127 (low/-) T cells: a more specific Treg population in human peripheral blood. Inflammation 2012;35:1773-1780.
14. Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH: Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med 2001;193:1285-1294.
15. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA: Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004;199:971-979.
16. Haas J, Hug A, Viehöver A, Fritzsching B, Falk CS, Filser A, Vetter T, Milkova L, Korporal M, Fritz B, Storch- Hagenlocher B, Krammer PH, Suri-Payer E, Wildemann B: Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur J Immunol 2005;35:3343-3352.
17. Kumar M, Putzki N, Limmroth V, Remus R, Lindemann M, Knop D, Mueller N, Hardt C, Kreuzfelder E, Grosse-Wilde H: CD4+CD25+FoxP3+ T lymphocytes fail to suppress myelin basic protein-induced proliferation in patients with multiple sclerosis. J Neuroimmunol 2006;180:178-184.
18. Venken K, Hellings N, Broekmans T, Hensen K, Rummens JL, Stinissen P: Natural naive CD4+CD25+CD127low regulatory T cell (Treg) development and function are disturbed in multiple sclerosis patients: recovery of memory Treg homeostasis during disease progression. J Immunol 2008;180:6411-6420.
19. Fletcher JM, Lonergan R, Costelloe L, Kinsella K, Moran B, O'Farrelly C, Tubridy N, Mills KH: CD39+Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis. J Immunol 2009;183:7602-7610.
20. Liu MF, Wang CR, Fung LL, Wu CR: Decreased CD4+CD25+ T cells in peripheral blood of patients with systemic lupus erythematosus. Scand J Immunol 2004;59:198-202.
21. Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, Mauri C: Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004;200:277-285.
22. Lindley S, Dayan CM, Bishop A, Roep BO, Peakman M, Tree TI: Defective suppressor function in CD4(+) CD25(+) T-cells from patients with type 1 diabetes. Diabetes 2005;54:92-99.
23. Brusko T, Wasserfall C, McGrail K, Schatz R, Viener HL, Schatz D, Haller M, Rockell J, Gottlieb P, Clare-Salzler M, Atkinson M: No alterations in the frequency of FOXP3+ regulatory T-cells in type 1 diabetes. Diabetes 2007;56:604-612.
24. Kleinewietfeld M, Starke M, Di Mitri D, Borsellino G, Battistini L, Rötzschke O, Falk K: CD49d provides access to "untouched" human Foxp3+ Treg free of contaminating effector cells. Blood 2009;113:827-836.
25. Barde MP, Barde PJ: What to use to express the variability of data: Standard deviation or standard error of mean? Perspect Clin Res 2012;3:113-116.
26. Jana S, Campbell H, Woodliff J, Waukau J, Jailwala P, Ghorai J, Ghosh S, Glisic S: The type of responder T-cell has a significant impact in a human in vitro suppression assay. PLoS One 2010;DOI: 10.1371/0015154.
27. Venigalla RK, Tretter T, Krienke S, Max R, Eckstein V, Blank N, Fiehn C, Ho AD, Lorenz HM: Reduced CD4+,CD25- T cell sensitivity to the suppressive function of CD4+,CD25high,CD127 -/low regulatory T cells in patients with active systemic lupus erythematosus. Arthritis Rheum 2008;58:2120-2130.
28. Lawson JM, Tremble J, Dayan C, Beyan H, Leslie RD, Peakman M, Tree TI: Increased resistance to CD4+CD25hi regulatory T cell-mediated suppression in patients with type 1 diabetes. Clin Exp Immunol 2008;154:353-359.
29. Schneider A, Rieck M, Sanda S, Pihoker C, Greenbaum C, Buckner JH: The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells. J Immunol 2008;181:7350-7355.
30. Xiao H, Wang S, Miao R, Kan W: TRAIL is associated with impaired regulation of CD4+CD25- T cells by regulatory T cells in patients with rheumatoid arthritis. J Clin Immunol 2011;31:1112-1119.
31. Schneider A, Long SA, Cerosaletti K, Ni CT, Samuels P, Kita M, Buckner JH: In active relapsing-remitting multiple sclerosis, effector T cell resistance to adaptive T(regs) involves IL-6-mediated signaling. Sci Transl Med 2013;DOI: 10.1126/3004970.